OBI Pharma Announces Presentations at ESMO Asia 2020 Virtual Annual Meeting for OBI-833, a Novel Anti-Globo H Targeted Therapeutic Cancer Vaccine
The Pharma Data
NOVEMBER 18, 2020
.” Ming-Tain Lai, PhD, Chief Scientific Officer at OBI Pharma stated, “In the trial, OBI-833 demonstrated a favorable safety profile and generated detectable anti-Globo H IgM/IgG responses. Title: A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients. Presenter: Ching-Liang Ho MD, et.al.
Let's personalize your content